Recent studies have shown that iPSC-CMs assembled into EHTs could be used to model contractile deficits of RBM20 p.R636S DCM variant,76 validate the effects of combinatorial tyrosine kinase inhibitor treatment in improving contractility in pathogenic DCM variants,65 and assess the efficacy of diltiazem for HCM personalized care.49 This evidence concerns the gene RBM20 and familial dilated cardiomyopathy.